Pharmacotherapy for Non-Alcoholic Fatty Liver Disease: Emerging Targets and Drug Candidates

Editorial Material Gastroenterology & Hepatology

Saroglitazar, a PPAR-α/γ Agonist, for Treatment of Nonalcoholic Fatty Liver Disease: A Randomized Controlled Double-Blind Phase 2 Trial

Manas Kumar Panigrahi et al.

JOURNAL OF CLINICAL AND EXPERIMENTAL HEPATOLOGY (2022)

Article Pharmacology & Pharmacy

Anthelmintics nitazoxanide protects against experimental hyperlipidemia and hepatic steatosis in hamsters and mice

Fengfeng Li et al.

Summary: Nitazoxanide, an FDA-approved drug, exhibits mild mitochondrial uncoupling and activates AMPK in liver cells. It shows therapeutic effects in improving hyperlipidemia and hepatic steatosis, making it a promising treatment option.

ACTA PHARMACEUTICA SINICA B (2022)

添加到收藏夹

Article Gastroenterology & Hepatology

Ipragliflozin Improves the Hepatic Outcomes of Patients With Diabetes with NAFLD

Hirokazu Takahashi et al.

Summary: Long-term treatment with ipragliflozin improves hepatic fibrosis in patients with NAFLD and may be effective for treating and preventing NASH in diabetes patients, while also improving glycemic control and obesity. Further larger studies are needed to confirm these effects.

HEPATOLOGY COMMUNICATIONS (2022)

添加到收藏夹

Article Gastroenterology & Hepatology

G-Protein-Coupled Receptors 120 Agonist III Improves Hepatic Inflammation and ER Stress in Steatohepatitis

Xiaoyuan Chen et al.

Summary: The study found that GPR120 agonist III has a significant inhibitory effect on steatohepatitis, reversing hepatic inflammation, ER stress, and apoptosis. This agonist provides a new approach for future treatments of human NAFLD/NASH.

DIGESTIVE DISEASES AND SCIENCES (2021)

添加到收藏夹

Review Medicine, Research & Experimental

Evolving Role for Pharmacotherapy in NAFLD/NASH

Suzanna L. Attia et al.

Summary: NAFLD is a prevalent and dynamic disease that can lead to serious complications, such as cirrhosis and hepatocellular carcinoma. Although there are currently no FDA-approved treatments for NAFLD, there is active research on emerging pharmacotherapies targeting various pathways within the liver. Promising phase III trials are ongoing, with obeticholic acid showing potential in reducing fibrosis in adults with NASH. Completed and ongoing clinical trials highlight the importance of understanding individualized approaches to pharmacotherapy based on NAFLD subgroups.

CTS-CLINICAL AND TRANSLATIONAL SCIENCE (2021)

添加到收藏夹

Review Endocrinology & Metabolism

Dipeptidyl Peptidase IV Inhibitors for Nonalcoholic Fatty Liver Disease - Systematic Review and Metanalysis

Lucas Ribeiro dos Santos et al.

Summary: Through meta-analysis, i DPP-IV showed a reduction in ALT and hepatic steatosis in NAFLD patients, but the overall quality of the studies was poor, and no significant efficacy was found on inflammatory markers or fibrosis.

CURRENT DIABETES REVIEWS (2021)

添加到收藏夹

Article Gastroenterology & Hepatology

Effect of 48-week pemafibrate on non-alcoholic fatty liver disease with hypertriglyceridemia, as evaluated by the FibroScan-aspartate aminotransferase score

Takeshi Hatanaka et al.

Summary: This study demonstrated that pemafibrate therapy significantly improved the FAST score in NAFLD patients, suggesting a preventive effect on disease progression in patients with hypertriglyceridemia.

JGH OPEN (2021)

添加到收藏夹

Article Gastroenterology & Hepatology

Randomised clinical trial: A phase 2 double-blind study of namodenoson in non-alcoholic fatty liver disease and steatohepatitis

Rifaat Safadi et al.

Summary: Namodenoson, an A3 adenosine receptor agonist, showed efficacy in improving liver function in patients with non-alcoholic fatty liver disease. The treatment resulted in dose-dependent reductions in serum ALT and AST levels, with the 25mg b.d. dose demonstrating significant effectiveness at 12 weeks.

ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2021)

添加到收藏夹

Article Biochemistry & Molecular Biology

The protective effects of trelagliptin on high-fat diet-induced nonalcoholic fatty liver disease in mice

Guang Wang et al.

Summary: Trelagliptin shows promising effects in reducing blood lipid levels, improving insulin resistance, alleviating liver function damage and oxidative stress, and exhibiting anti-inflammatory properties in a mouse model of NAFLD.

JOURNAL OF BIOCHEMICAL AND MOLECULAR TOXICOLOGY (2021)

添加到收藏夹

Article Medicine, General & Internal

A novel GLP-1 and FGF21 dual agonist has therapeutic potential for diabetes and non-alcoholic steatohepatitis

Qi Pan et al.

Summary: Novel FGF21-Fc-GLP-1 dual-targeted constructs were developed with enhanced activity and prolonged half-life in vivo, showing promising effects in glucose lowering, weight loss, and anti-NASH in various experiments.

EBIOMEDICINE (2021)

添加到收藏夹

Article Oncology

Namodenoson in Advanced Hepatocellular Carcinoma and Child-Pugh B Cirrhosis: Randomized Placebo-Controlled Clinical Trial

Salomon M. Stemmer et al.

Summary: Namodenoson did not show an overall survival advantage in patients with advanced hepatocellular carcinoma and moderate hepatic dysfunction, but demonstrated a significant improvement in patients with CP score of 7. The drug was well-tolerated and had a safety profile comparable to the placebo group.

CANCERS (2021)

添加到收藏夹

Article Pharmacology & Pharmacy

Protective effect of SGL5213, a potent intestinal sodium-glucose cotransporter 1 inhibitor, in nonalcoholic fatty liver disease in mice

Yasushi Honda et al.

Summary: SGL5213 demonstrated a protective effect in a rodent model of NAFLD, potentially by inhibiting glucose absorption and increasing glucose content in the gastrointestinal tract. It is considered a promising therapeutic agent for NAFLD with obesity and insulin resistance.

JOURNAL OF PHARMACOLOGICAL SCIENCES (2021)

添加到收藏夹

Article Gastroenterology & Hepatology

Combination Therapies Including Cilofexor and Firsocostat for Bridging Fibrosis and Cirrhosis Attributable to NASH

Rohit Loomba et al.

Summary: In patients with bridging fibrosis and cirrhosis, 48 weeks of treatment with cilofexor/firsocostat was well tolerated and resulted in improvements in NASH activity, potentially having an antifibrotic effect. This combination offers potential for fibrosis regression with longer-term therapy in patients with advanced fibrosis attributable to NASH.

HEPATOLOGY (2021)

添加到收藏夹

Article Biochemistry & Molecular Biology

Aramchol in patients with nonalcoholic steatohepatitis: a randomized, double-blind, placebo-controlled phase 2b trial

V. Ratziu et al.

Summary: Aramchol showed potential improvements in liver steatosis and fibrosis in NASH patients, but did not significantly reduce hepatic triglycerides. However, it demonstrated positive effects on liver histology and ALT levels in the clinical trial.

NATURE MEDICINE (2021)

添加到收藏夹

Article Biochemistry & Molecular Biology

ACC inhibitor alone or co-administered with a DGAT2 inhibitor in patients with non-alcoholic fatty liver disease: two parallel, placebo-controlled, randomized phase 2a trials

Roberto A. Calle et al.

Summary: The study showed that ACC1/2 inhibitors had a good therapeutic effect in the treatment of non-alcoholic fatty liver disease, significantly reducing liver fat content. Co-administration of PF-05221304 and PF-06865571 can reduce the incidence of adverse events and mitigate the effect of ACC inhibition on serum triglycerides.

NATURE MEDICINE (2021)

添加到收藏夹

Article Medicine, General & Internal

A Randomized, Controlled Trial of the Pan-PPAR Agonist Lanifibranor in NASH

Sven M. Francque et al.

Summary: In a randomized trial, the pan-PPAR agonist Lanifibranor showed significant improvement in histologic features of NASH at a dose of 1200 mg. However, adverse events such as weight gain, anemia, peripheral edema, diarrhea, and nausea were more common with Lanifibranor compared to placebo.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

添加到收藏夹

News Item Gastroenterology & Hepatology

Research in brief

Holly Baker

LANCET GASTROENTEROLOGY & HEPATOLOGY (2021)

添加到收藏夹

Review Gastroenterology & Hepatology

G protein-coupled receptors as potential targets for nonalcoholic fatty liver disease treatment

Ming Yang et al.

Summary: Nonalcoholic fatty liver disease is a spectrum of diseases, with abnormal hepatic lipid accumulation being a major feature. G protein-coupled receptors play crucial roles in metabolic disorders and their connections to gut microbiota-mediated diseases. Understanding GPCR-mediated signaling in liver disease may offer new therapeutic options for NAFLD.

WORLD JOURNAL OF GASTROENTEROLOGY (2021)

添加到收藏夹

Article Endocrinology & Metabolism

Beneficial effect of omarigliptin on diabetic patients with non-alcoholic fatty liver disease/non-alcoholic steatohepatitis

Sachiko Hattori et al.

Summary: The study indicates that weekly administration of the DPP4 inhibitor omarigliptin (OMG) can significantly improve liver function and reduce inflammation and insulin resistance levels in type 2 diabetic patients with NAFLD, and also has positive effects on liver function and fibrosis in NASH patients.

DIABETOLOGY & METABOLIC SYNDROME (2021)

添加到收藏夹

Review Endocrinology & Metabolism

Alternative RNA Splicing in Fatty Liver Disease

Panyisha Wu et al.

Summary: Alternative RNA splicing is an important biological process that has been linked to various clinical syndromes, but its applicability to common diseases is still uncertain. This review focuses on the changes in alternative RNA splicing in fatty liver disease and the role of splicing regulation in disease progression.

FRONTIERS IN ENDOCRINOLOGY (2021)

添加到收藏夹

Article Multidisciplinary Sciences

GIP mediates the incretin effect and glucose tolerance by dual actions on α cells and β cells

K. El et al.

Summary: The study reveals that GIP enhances amino acid-stimulated glucagon secretion and plays a role in insulin secretion by promoting paracrine alpha to beta cell communication. Loss of GIPR activity in alpha cells prevents glucagon secretion in response to a meal stimulus, affecting insulin secretion and leading to glucose intolerance.

SCIENCE ADVANCES (2021)

添加到收藏夹

Article Endocrinology & Metabolism

Comparing the effects of tofogliflozin and pioglitazone in non-alcoholic fatty liver disease patients with type 2 diabetes mellitus (ToPiND study): a randomized prospective open-label controlled trial

Masato Yoneda et al.

Summary: The study compared the effectiveness of tofogliflozin and pioglitazone for the treatment of NAFLD patients with type 2 diabetes mellitus, showing that both medications significantly reduced hepatic fat content. Tofogliflozin led to greater weight loss compared to pioglitazone, with both drugs being well tolerated.

BMJ OPEN DIABETES RESEARCH & CARE (2021)

添加到收藏夹

Article Multidisciplinary Sciences

A meta-analysis of the effects of glucagon-like-peptide 1 receptor agonist (GLP1-RA) in nonalcoholic fatty liver disease (NAFLD) with type 2 diabetes (T2D)

Samit Ghosal et al.

Summary: GLP1-RA treatment shows significant improvement in liver function, weight reduction, decrease in liver fat content, better glycemic control, and reduction in hepatic inflammation for patients with both T2D and NAFLD.

SCIENTIFIC REPORTS (2021)

添加到收藏夹

Article Pharmacology & Pharmacy

What considerations are there for the pharmacotherapeutic management of nonalcoholic steatohepatitis?

Masato Yoneda et al.

EXPERT OPINION ON PHARMACOTHERAPY (2021)

添加到收藏夹

Article Gastroenterology & Hepatology

Nitazoxanide versus rifaximin in preventing the recurrence of hepatic encephalopathy: A randomized double-blind controlled trial

Khadija A. M. Glal et al.

Summary: The study evaluated the safety and efficacy of nitazoxanide compared to rifaximin in preventing the recurrence of hepatic encephalopathy, with patients in the NTZ group showing significant improvements in neurological symptoms, mental status, and quality of life.

JOURNAL OF HEPATO-BILIARY-PANCREATIC SCIENCES (2021)

添加到收藏夹

Editorial Material Gastroenterology & Hepatology

FXR agonists for NASH: How are they different and what difference do they make?

Claus Kremoser

JOURNAL OF HEPATOLOGY (2021)

添加到收藏夹

Review Medicine, General & Internal

Role of Galectins in the Liver Diseases: A Systematic Review and Meta-Analysis

Yang An et al.

Summary: High expression of Galectin-1 and -3 is associated with worse outcomes in hepatocellular carcinoma patients, while high expression of Galectin-4 and -9 is associated with better outcomes. Serum Galectin-3 and -9 levels are positively associated with the risk of chronic liver diseases.

FRONTIERS IN MEDICINE (2021)

添加到收藏夹

Article Biochemistry & Molecular Biology

Therapeutic Opportunities of IL-22 in Non-Alcoholic Fatty Liver Disease: From Molecular Mechanisms to Clinical Applications

Wenjing Zai et al.

Summary: IL-22 plays an important protective role in nonalcoholic fatty liver disease, improving the condition through various pathways and alleviating hepatitis and steatosis by activating different signaling pathways. Modifications are needed to enhance its efficacy and reduce systemic side effects for further clinical application.

BIOMEDICINES (2021)

添加到收藏夹

Article Medicine, General & Internal

A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis

Philip N. Newsome et al.

Summary: This phase 2 trial demonstrated that treatment with semaglutide resulted in a significantly higher percentage of patients with NASH resolution compared to placebo in patients with NASH, but did not show a significant between-group difference in the percentage of patients with an improvement in fibrosis stage.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

添加到收藏夹

Review Pharmacology & Pharmacy

Therapeutic targets, novel drugs, and delivery systems for diabetes associated NAFLD and liver fibrosis

Virender Kumar et al.

Summary: Type 2 diabetes mellitus associated non-alcoholic fatty liver disease is the fourth leading cause of death, with complications such as nephropathy and cirrhosis. Etiological factors involve hyperglycemia and insulin resistance, with treatment targets including FFA homeostasis and lipid metabolism. Strategies to enhance drug delivery to specific liver cell types have the potential to improve efficacy and reduce off-target effects.

ADVANCED DRUG DELIVERY REVIEWS (2021)

添加到收藏夹

Review Biochemistry & Molecular Biology

FXR in liver physiology: Multiple faces to regulate liver metabolism

Katrin Panzitt et al.

Summary: The liver serves as a central metabolic hub that coordinates nutritional inputs and metabolic outputs. FXR in the liver and intestine plays a crucial role in regulating postprandial nutrient disposal. Aside from classical roles, FXR also has effects on amino acid, protein metabolism, autophagic turnover, and inflammation, which are less studied. Additionally, understanding of how FXR signaling is affected by posttranslational modifications and different isoforms is important for potential pharmaceutical targeting in clinical applications.

BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE (2021)

添加到收藏夹

Article Endocrinology & Metabolism

Effects of Cotadutide on Metabolic and Hepatic Parameters in Adults With Overweight or Obesity and Type 2 Diabetes: A 54-Week Randomized Phase 2b Study

Rajaa Nahra et al.

Summary: Cotadutide treatment for 54 weeks improved glycemic control and weight loss in participants with overweight/obesity and type 2 diabetes. Ad hoc analyses demonstrated improvements in hepatic parameters and support further evaluation of cotadutide in NASH.

DIABETES CARE (2021)

添加到收藏夹

Article Biochemistry & Molecular Biology

Efruxifermin in non-alcoholic steatohepatitis: a randomized, double-blind, placebo-controlled, phase 2a trial

Stephen A. Harrison et al.

Summary: The study demonstrated the efficacy of efruxifermin in treating NASH by significantly reducing HFF levels in patients, with an acceptable safety profile.

NATURE MEDICINE (2021)

添加到收藏夹

Article Multidisciplinary Sciences

A phase 2, proof of concept, randomised controlled trial of berberine ursodeoxycholate in patients with presumed non-alcoholic steatohepatitis and type 2 diabetes

Stephen A. Harrison et al.

Summary: In this study, a clinical trial was conducted to test the effects of berberine ursodeoxycholate on patients with fatty liver disease and diabetes, showing that a higher dose of the drug led to reduced liver fat content. The results suggest that berberine ursodeoxycholate has a broad spectrum of metabolic activity in patients with presumed NASH and diabetes, is relatively well tolerated, and deserves further development as a treatment for NASH with diabetes.

NATURE COMMUNICATIONS (2021)

添加到收藏夹

Review Chemistry, Medicinal

Non-Alcoholic Steatohepatitis (NASH) - A Review of a Crowded Clinical Landscape, Driven by a Complex Disease

Julia M. Fraile et al.

Summary: Non-alcoholic steatohepatitis (NASH) is a common chronic liver condition with no FDA-approved therapies. Despite a growing market and clinical need, finding effective drugs has been challenging. Several drug candidates are in late-stage clinical trials, but the complex pathophysiology of NASH may require drug combination and targeting of different stages of the disease.

DRUG DESIGN DEVELOPMENT AND THERAPY (2021)

添加到收藏夹

Article Cell Biology

Eritoran Attenuates Hepatic Inflammation and Fibrosis in Mice with Chronic Liver Injury

Yun-Cheng Hsieh et al.

Summary: The study showed that the TLR4 signaling pathway plays a crucial role in chronic liver injury, and eritoran demonstrated potential therapeutic effects by inhibiting this pathway. Eritoran was found to alleviate hepatic inflammation and fibrosis in mice models, indicating its potential as a treatment for chronic liver disease.

CELLS (2021)

添加到收藏夹

Editorial Material Gastroenterology & Hepatology

Semaglutide for nonalcoholic steatohepatitis: closer to a solution?

Christina Liava et al.

HEPATOBILIARY SURGERY AND NUTRITION (2021)

添加到收藏夹

Article Gastroenterology & Hepatology

Efficacy and safety of PXL770, a direct AMP kinase activator, for the treatment of non-alcoholic fatty liver disease (STAMP-NAFLD): a randomised, double-blind, placebo- controlled, phase 2a study

Kenneth Cusi et al.

Summary: The study evaluated the efficacy and safety of PXL770 in patients with non-alcoholic fatty liver disease, showing that PXL770 treatment did not improve liver fat content but was well tolerated. AMPK activation might be a promising pharmacological target for patients with type 2 diabetes and NAFLD.

LANCET GASTROENTEROLOGY & HEPATOLOGY (2021)

添加到收藏夹

Article Gastroenterology & Hepatology

Saroglitazar, a PPAR-α/γ Agonist, for Treatment of NAFLD: A Randomized Controlled Double-Blind Phase 2 Trial

Samer Gawrieh et al.

Summary: Saroglitazar showed significant efficacy in patients with NAFLD/NASH, improving ALT, liver fat content and insulin resistance. The 4mg dose of Saroglitazar also demonstrated significant improvements in lipid metabolism and lipoprotein particle composition. Overall, Saroglitazar was well-tolerated with a slight weight gain observed in patients.

HEPATOLOGY (2021)

添加到收藏夹

Review Gastroenterology & Hepatology

New targets for NAFLD

Lucia Parlati et al.

Summary: Non-alcoholic fatty liver disease (NAFLD) is a growing cause of chronic liver disease worldwide with no effective treatments currently available. Preclinical models have enhanced our understanding of its pathophysiology, and research on new therapeutic targets is ongoing.

JHEP REPORTS (2021)

添加到收藏夹

Review Gastroenterology & Hepatology

Bile acid activated receptors: Integrating immune and metabolic regulation in non-alcoholic fatty liver disease

Michele Biagioli et al.

Summary: Bile acid activated receptors such as FXR and GPBAR1 play crucial roles in regulating lipid and glucose metabolism, making them potential drug targets for metabolic and inflammatory disorders. Dual FXR/GPBAR1 ligands have been developed for the treatment of metabolic disorders and are now in clinical trials.

LIVER RESEARCH (2021)

添加到收藏夹

Article Gastroenterology & Hepatology

A phase II study of human allogeneic liver-derived progenitor cell therapy for acute-on-chronic liver failure and acute decompensation

Frederik Nevens et al.

Summary: The study demonstrated the safety of treating patients with ACLF or AD with human allogeneic liver-derived progenitor cells within a certain dosage range and showed gradual improvement in systemic inflammation and liver function for the patients.

JHEP REPORTS (2021)

添加到收藏夹

Review Biochemistry & Molecular Biology

Farnesoid X receptor (FXR): Structures and ligands

Longying Jiang et al.

Summary: FXR is a crucial bile acid activated nuclear receptor that regulates key genes involved in bile acid metabolism. With the approval of OCA as the first small molecule targeting FXR, many other FXR-targeting small molecules are currently being evaluated in clinical trials.

COMPUTATIONAL AND STRUCTURAL BIOTECHNOLOGY JOURNAL (2021)

添加到收藏夹

Article Gastroenterology & Hepatology

Aramchol downregulates stearoyl CoA-desaturase 1 in hepatic stellate cells to attenuate cellular fibrogenesis

Dipankar Bhattacharya et al.

Summary: This study investigates the potential activity of Aramchol in blocking fibrosis by hepatic stellate cells, primarily through inhibiting SCD1 and reducing fibrogenic gene expression while inducing protective gene PPARG. These findings suggest novel mechanisms of Aramchol activity in NASH patients.

JHEP REPORTS (2021)

添加到收藏夹

Review Biochemistry & Molecular Biology

MicroRNAs in the Pathogenesis of Nonalcoholic Fatty Liver Disease

Zhiqiang Fang et al.

Summary: NAFLD is a chronic liver disorder closely associated with cardiovascular disease, obesity, and type 2 diabetes mellitus worldwide. Recent studies have found that miRNAs play crucial roles in the pathogenesis and progression of NAFLD, suggesting them as potential therapeutic targets.

INTERNATIONAL JOURNAL OF BIOLOGICAL SCIENCES (2021)

添加到收藏夹

Article Gastroenterology & Hepatology

Deuterium-Stabilized (R)-Pioglitazone (PXL065) Is Responsible for Pioglitazone Efficacy in NASH yet Exhibits Little to No PPARγ Activity

Vincent Jacques et al.

Summary: Pioglitazone is a potent drug for treating NASH in non-diabetic or diabetic patients, but its side effects include weight gain and edema. Stabilized stereoisomers of pioglitazone showed that (R)-pioglitazone retains efficacy in NASH without the PPAR γ activity associated with weight gain observed in (S)-pioglitazone.

HEPATOLOGY COMMUNICATIONS (2021)

添加到收藏夹

Article Gastroenterology & Hepatology

Effects of Resmetirom on Noninvasive Endpoints in a 36-Week Phase 2 Active Treatment Extension Study in Patients With NASH

Stephen A. Harrison et al.

Summary: The study demonstrated significant improvements in liver fat reduction, lipid metabolism, and fibrosis markers reduction in NASH patients treated with resmetirom for 36 weeks. Resmetirom showed good tolerability and safety in patients with NASH.

HEPATOLOGY COMMUNICATIONS (2021)

添加到收藏夹

Review Biochemistry & Molecular Biology

Role of lysophosphatidic acid and its receptors in health and disease: novel therapeutic strategies

Luiz Henrique Medeiros Geraldo et al.

Summary: Lysophosphatidic acid (LPA) is a versatile bioactive phospholipid that can signal through specific receptors to have diverse effects in central nervous system development and angiogenesis, as well as acting as a potent mediator in neuropathic pain, neurodegenerative diseases, and cancer progression. Understanding the production and signaling mechanisms of LPA is crucial for comprehending its biological functions in the central nervous system in both health and disease states.

SIGNAL TRANSDUCTION AND TARGETED THERAPY (2021)

添加到收藏夹

Article Gastroenterology & Hepatology

Empagliflozin for the Treatment of Nonalcoholic Steatohepatitis in Patients with Type 2 Diabetes Mellitus

Lee-Lee Lai et al.

DIGESTIVE DISEASES AND SCIENCES (2020)

添加到收藏夹

Article Gastroenterology & Hepatology

Fatty Acid Synthase Inhibitor TVB-2640 Reduces Hepatic de Novo Lipogenesis in Males With Metabolic Abnormalities

Majid M. Syed-Abdul et al.

HEPATOLOGY (2020)

添加到收藏夹

Article Gastroenterology & Hepatology

Insulin sensitizer MSDC-0602K in non-alcoholic steatohepatitis: A randomized, double-blind, placebo-controlled phase IIb study

Stephen A. Harrison et al.

JOURNAL OF HEPATOLOGY (2020)

添加到收藏夹

Review Biochemistry & Molecular Biology

The influence of Glucose-dependent Insulinotropic Polypeptide (GIP) on human adipose tissue and fat metabolism: Implications for obesity, type 2 diabetes and Non-Alcoholic Fatty Liver Disease (NAFLD)

Sravan K. Thondam et al.

PEPTIDES (2020)

添加到收藏夹

Meeting Abstract Gastroenterology & Hepatology

Tropifexor, a highly potent FXR agonist, produces robust and dose-dependent reductions in hepatic fat and serum alanine aminotransferase in patients with fibrotic NASH after 12 weeks of therapy: FLIGHT-FXR Part C interim results

K. J. Lucas et al.

DIGESTIVE AND LIVER DISEASE (2020)

添加到收藏夹

Article Gastroenterology & Hepatology

Effects of Belapectin, an Inhibitor of Galectin-3, in Patients With Nonalcoholic Steatohepatitis With Cirrhosis and Portal Hypertension

Naga Chalasani et al.

GASTROENTEROLOGY (2020)

添加到收藏夹

Editorial Material Gastroenterology & Hepatology

Redefining non-alcoholic fatty liver disease: what's in a name?

[Anonymous]

LANCET GASTROENTEROLOGY & HEPATOLOGY (2020)

添加到收藏夹

Article Gastroenterology & Hepatology

Cilofexor, a NonsteroidalFXRAgonist, in Patients With Noncirrhotic NASH: A Phase 2 Randomized Controlled Trial

Keyur Patel et al.

HEPATOLOGY (2020)

添加到收藏夹

Article Gastroenterology & Hepatology

Newly identified peptide hormone inhibits intestinal fat absorption and improves NAFLD through its receptor GPRC6A

Bin Teng et al.

JOURNAL OF HEPATOLOGY (2020)

添加到收藏夹

Review Cell Biology

Anti-NASH Drug Development Hitches a Lift on PPAR Agonism

Joost Boeckmans et al.

CELLS (2020)

添加到收藏夹

Review Cell Biology

Hepatocyte Injury and Hepatic Stem Cell Niche in the Progression of Non-Alcoholic Steatohepatitis

Diletta Overi et al.

CELLS (2020)

添加到收藏夹

Article Multidisciplinary Sciences

Dipeptidyl peptidase-4 inhibition prevents nonalcoholic steatohepatitis-associated liver fibrosis and tumor development in mice independently of its anti-diabetic effects

Mitsuhiro Kawakubo et al.

SCIENTIFIC REPORTS (2020)

添加到收藏夹

Review Pharmacology & Pharmacy

Effect of ursodeoxycholic acid on liver markers: A systematic review and meta-analysis of randomized placebo-controlled clinical trials

Mario Simental-Mendia et al.

BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2020)

添加到收藏夹

Article Endocrinology & Metabolism

Effects of Novel Dual GIP and GLP-1 Receptor Agonist Tirzepatide on Biomarkers of Nonalcoholic Steatohepatitis in Patients With Type 2 Diabetes

Mark L. Hartman et al.

DIABETES CARE (2020)

添加到收藏夹

Review Pharmacology & Pharmacy

Sirtuins: potential therapeutic targets for regulating acute inflammatory response?

Vidula Vachharajani et al.

EXPERT OPINION ON THERAPEUTIC TARGETS (2020)

添加到收藏夹

Review Gastroenterology & Hepatology

Lysyl Oxidase (LOX) Family Members: Rationale and Their Potential as Therapeutic Targets for Liver Fibrosis

Wei Chen et al.

HEPATOLOGY (2020)

添加到收藏夹

Review Gastroenterology & Hepatology

Genetic Pathways in Nonalcoholic Fatty Liver Disease: Insights From Systems Biology

Silvia Sookoian et al.

HEPATOLOGY (2020)

添加到收藏夹

Article Gastroenterology & Hepatology

A novel non-bile acid FXR agonist EDP-305 potently suppresses liver injury and fibrosis without worsening of ductular reaction

Ping An et al.

LIVER INTERNATIONAL (2020)

添加到收藏夹

Article Immunology

LOXL2 Inhibition Paves the Way for Macrophage-Mediated Collagen Degradation in Liver Fibrosis

Mordehay Klepfish et al.

FRONTIERS IN IMMUNOLOGY (2020)

添加到收藏夹

Article Medicine, General & Internal

The Medium-Chain Fatty Acid Receptor GPR84 Mediates Myeloid Cell Infiltration Promoting Steatohepatitis and Fibrosis

Tobias Puengel et al.

JOURNAL OF CLINICAL MEDICINE (2020)

添加到收藏夹

Article Cell Biology

EX-527 Prevents the Progression of High-Fat Diet-Induced Hepatic Steatosis and Fibrosis by Upregulating SIRT4 in Zucker Rats

Amit Kundu et al.

CELLS (2020)

添加到收藏夹

Article Cell Biology

Pirfenidone Inhibits Cell Proliferation and Collagen I Production of Primary Human Intestinal Fibroblasts

Yingying Cui et al.

CELLS (2020)

添加到收藏夹

Meeting Abstract Endocrinology & Metabolism

HM15211, a Novel Long-Acting GLP-1/GIP/Glucagon Triple Agonist, Exhibits Anti-inflammatory and Fibrotic Effects in AMLN/TAA-Induced Liver Inflammation and Fibrosis Mice

Jung Kuk Kim et al.

DIABETES (2020)

添加到收藏夹

Meeting Abstract Endocrinology & Metabolism

Oral Insulin-Induced Reduction in Liver Fat Content in T2DM Patients with Nonalcoholic Steatohepatitis

Miriam Kidron et al.

DIABETES (2020)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

Effects of Epeleuton, a Novel Synthetic Second-Generation n-3 Fatty Acid, on Non-Alcoholic Fatty Liver Disease, Triglycerides, Glycemic Control, and Cardiometabolic and Inflammatory Markers

John Climax et al.

JOURNAL OF THE AMERICAN HEART ASSOCIATION (2020)

添加到收藏夹

Review Biochemistry & Molecular Biology

Relevance of SIRT1-NF-κB Axis as Therapeutic Target to Ameliorate Inflammation in Liver Disease

Estefania de Gregorio et al.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2020)

添加到收藏夹

Article Endocrinology & Metabolism

Effects of Ertugliflozin on Liver Enzymes in Patients with Type 2 Diabetes: A Post-Hoc Pooled Analysis of Phase 3 Trials

Silvina Gallo et al.

DIABETES THERAPY (2020)

添加到收藏夹

Article Gastroenterology & Hepatology

Novel antisense inhibition of diacylglycerol O-acyltransferase 2 for treatment of non-alcoholic fatty liver disease: a multicentre, double-blind, randomised, placebo-controlled phase 2 trial

Rohit Loomba et al.

LANCET GASTROENTEROLOGY & HEPATOLOGY (2020)

添加到收藏夹

Review Cell Biology

The roles of galectins in hepatic diseases

Mei-Juan Sun et al.

JOURNAL OF MOLECULAR HISTOLOGY (2020)

添加到收藏夹

Article Medicine, Research & Experimental

Effect of Empagliflozin on Liver Steatosis and Fibrosis in Patients With Non-Alcoholic Fatty Liver Disease Without Diabetes: A Randomized, Double-Blind, Placebo-Controlled Trial

Hoda Taheri et al.

ADVANCES IN THERAPY (2020)

添加到收藏夹

Article Pharmacology & Pharmacy

The GPR40 Full Agonist SCO-267 Improves Liver Parameters in a Mouse Model of Nonalcoholic Fatty Liver Disease without Affecting Glucose or Body Weight

Mitsugi Ookawara et al.

JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2020)

添加到收藏夹

Article Endocrinology & Metabolism

Effect of dulaglutide on liver fat in patients with type 2 diabetes and NAFLD: randomised controlled trial (D-LIFT trial)

Mohammad S. Kuchay et al.

DIABETOLOGIA (2020)

添加到收藏夹

Article Gastroenterology & Hepatology

Benefits of prolonged-release pirfenidone plus standard of care treatment in patients with advanced liver fibrosis: PROMETEO study

Jorge Luis Poo et al.

HEPATOLOGY INTERNATIONAL (2020)

添加到收藏夹

Article Multidisciplinary Sciences

Fatty acid mimetic PBI-4547 restores metabolic homeostasis via GPR84 in mice with non-alcoholic fatty liver disease

Jean-Christophe Simard et al.

SCIENTIFIC REPORTS (2020)

添加到收藏夹

Article Gastroenterology & Hepatology

EDP-297, a novel and potent fxr agonist, exhibit robust anti-fibrotic effects with significant liver function in a rat model of non-alcoholic steatohepatitis

Mozhdeh Sojoodi et al.

JOURNAL OF HEPATOLOGY (2020)

添加到收藏夹

Article Gastroenterology & Hepatology

Synergistic effect of clostridium butyricum miyairi on rifaximin in mice model of non-alcoholic steatohepatitis by methionine choline-deficient diet

Ryo Yamauchi et al.

JOURNAL OF HEPATOLOGY (2020)

添加到收藏夹

Article Gastroenterology & Hepatology

Co-administration of PF-05221304 and PF-06865571 delivers robust whole liver fat reduction and mitigation of acetyl-coa carboxilase inhibitor induced hypertriglyceridemia in patients with NAFLD

Roberto Calle et al.

JOURNAL OF HEPATOLOGY (2020)

添加到收藏夹

Review Nutrition & Dietetics

Effects of Omega-3 Polyunsaturated Fatty Acid Supplementation on Non-Alcoholic Fatty Liver: A Systematic Review and Meta-Analysis

Cheng-Han Lee et al.

NUTRIENTS (2020)

添加到收藏夹

Article Biochemistry & Molecular Biology

Mitochondrial Transfer by Human Mesenchymal Stromal Cells Ameliorates Hepatocyte Lipid Load in a Mouse Model of NASH

Mei-Ju Hsu et al.

BIOMEDICINES (2020)

添加到收藏夹

Article Multidisciplinary Sciences

Saroglitazar in patients with non-alcoholic fatty liver disease and diabetic dyslipidemia: a prospective, observational, real world study

Omesh Goyal et al.

SCIENTIFIC REPORTS (2020)

添加到收藏夹

Review Endocrinology & Metabolism

FGF19 and FGF21 for the Treatment of NASH-Two Sides of the Same Coin? Differential and Overlapping Effects of FGF19 and FGF21 From Mice to Human

Emma Henriksson et al.

FRONTIERS IN ENDOCRINOLOGY (2020)

添加到收藏夹

Review Endocrinology & Metabolism

Chronic Inflammation in Non-Alcoholic Steatohepatitis: Molecular Mechanisms and Therapeutic Strategies

Carmelo Luci et al.

FRONTIERS IN ENDOCRINOLOGY (2020)

添加到收藏夹

Article Gastroenterology & Hepatology

Effects of proprotein convertase subtilisin/kexin type-9 inhibitors on fatty liver

Muhammad Shafiq et al.

WORLD JOURNAL OF HEPATOLOGY (2020)

添加到收藏夹

Article Multidisciplinary Sciences

Antibody-mediated activation of the FGFR1/Klothoβ complex corrects metabolic dysfunction and alters food preference in obese humans

Amos Baruch et al.

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2020)

添加到收藏夹

Article Physiology

Diacylglycerol acyltransferase 1/2 inhibition induces dysregulation of fatty acid metabolism and leads to intestinal barrier failure and diarrhea in mice

Kosuke Takemoto et al.

PHYSIOLOGICAL REPORTS (2020)

添加到收藏夹

Review Gastroenterology & Hepatology

Glucagon-like peptide-1 receptor agonists in non-alcoholic fatty liver disease: An update

Areti Sofogianni et al.

WORLD JOURNAL OF HEPATOLOGY (2020)

添加到收藏夹

Article Endocrinology & Metabolism

Resolution of NASH and hepatic fibrosis by the GLP-1R and GCGR dual-agonist cotadutide via modulating mitochondrial function and lipogenesis

Michelle L. Boland et al.

NATURE METABOLISM (2020)

添加到收藏夹

Review Medicine, Research & Experimental

SGLT2 Inhibitors: The Star in the Treatment of Type 2 Diabetes?

Yoshifumi Saisho

DISEASES (2020)

添加到收藏夹

Article Gastroenterology & Hepatology

A blocking monoclonal antibody to CCL24 alleviates liver fibrosis and inflammation in experimental models of liver damage

Michal Segal-Salto et al.

JHEP REPORTS (2020)

添加到收藏夹

Article Medicine, General & Internal

EFFECTS OF EMPAGLIFLOZIN AND L-ORNITHINE L-ASPARTATE ON BEHAVIOR, COGNITIVE FUNCTIONS, AND PHYSICAL PERFORMANCE IN MICE WITH EXPERIMENTALLY INDUCED STEATOHEPATITIS

V. A. Prikhodko et al.

BULLETIN OF RUSSIAN STATE MEDICAL UNIVERSITY (2020)

添加到收藏夹

Article Gastroenterology & Hepatology

Effect of luseogliflozin on hepatic fat content in type 2 diabetes patients with non-alcoholic fatty liver disease: A prospective, single-arm trial (LEAD trial)

Yoshio Sumida et al.

HEPATOLOGY RESEARCH (2019)

添加到收藏夹

Article Endocrinology & Metabolism

The effects of licogliflozin, a dual SGLT1/2 inhibitor, on body weight in obese patients with or without diabetes

Yan-Ling He et al.

DIABETES OBESITY & METABOLISM (2019)

添加到收藏夹

Article Medicine, General & Internal

The efficacy of saxagliptin in T2DM patients with non-alccholic fatty liver disease: preliminary data

Juan-Juan Li et al.

REVISTA DA ASSOCIACAO MEDICA BRASILEIRA (2019)

添加到收藏夹

Editorial Material Medicine, General & Internal

The utility of ezetimibe therapy in nonalcoholic fatty liver disease

Baek Gyu Jun et al.

KOREAN JOURNAL OF INTERNAL MEDICINE (2019)

添加到收藏夹

Article Gastroenterology & Hepatology

Inhibiting Interleukin 11 Signaling Reduces Hepatocyte Death and Liver Fibrosis, Inflammation, and Steatosis in Mouse Models of Nonalcoholic Steatohepatitis

Anissa A. Widjaja et al.

GASTROENTEROLOGY (2019)

添加到收藏夹

Meeting Abstract Gastroenterology & Hepatology

VK2809, a Novel Liver-Directed Thyroid Receptor Beta Agonist, Significantly Reduces Liver Fat with Both Low and High Doses in Patients with Non-Alcoholic Fatty Liver Disease: A Phase 2 Randomized, Placebo-Controlled Trial

Rohit Loomba et al.

JOURNAL OF HEPATOLOGY (2019)

添加到收藏夹

Meeting Abstract Endocrinology & Metabolism

Teneligliptin Significantly Reduces Liver Fat Content (LFC) and Delays Progression of NASH in Type 2 Diabetes Mellitus Patients

Vishal Kumar Gupta

DIABETES (2019)

添加到收藏夹

Article Multidisciplinary Sciences

Randomized, Double-blind, Placebo-controlled Study of a Multispecies Probiotic Mixture in Nonalcoholic Fatty Liver Disease

Sang Bong Anh et al.

SCIENTIFIC REPORTS (2019)

添加到收藏夹

Review Endocrinology & Metabolism

Systematic Review and Meta-Analysis of Randomized Controlled Trials on the Effect of SGLT2 Inhibitor on Blood Leptin and Adiponectin Level in Patients with Type 2 Diabetes

Peili Wu et al.

HORMONE AND METABOLIC RESEARCH (2019)

添加到收藏夹

Review Endocrinology & Metabolism

The Role of Thyroid Hormones in Hepatocyte Proliferation and Liver Cancer

Fabio Gionfra et al.

FRONTIERS IN ENDOCRINOLOGY (2019)

添加到收藏夹

Review Nutrition & Dietetics

The Role of Probiotics in Nonalcoholic Fatty Liver Disease: A New Insight into Therapeutic Strategies

Marica Meroni et al.

NUTRIENTS (2019)

添加到收藏夹

Article Cell Biology

The lysyl oxidase like 2/3 enzymatic inhibitor, PXS-5153A, reduces crosslinks and ameliorates fibrosis

Heidi Schilter et al.

JOURNAL OF CELLULAR AND MOLECULAR MEDICINE (2019)

添加到收藏夹

Article Biochemistry & Molecular Biology

Effect of sodium-glucose cotransporter 2 inhibitor, empagliflozin, and α-glucosidase inhibitor, voglibose, on hepatic steatosis in an animal model of type 2 diabetes

Ji-Won Kim et al.

JOURNAL OF CELLULAR BIOCHEMISTRY (2019)

添加到收藏夹

Article Medicine, General & Internal

Effect of Lactobacillus paracasei N1115 and fructooligosaccharides in nonalcoholic fatty liver disease

Fangfang Yao et al.

ARCHIVES OF MEDICAL SCIENCE (2019)

添加到收藏夹

Article Gastroenterology & Hepatology

Effect of a Multistrain Probiotic on Cognitive Function and Risk of Falls in Patients With Cirrhosis: A Randomized Trial

Eva Roman et al.

HEPATOLOGY COMMUNICATIONS (2019)

添加到收藏夹

Article Gastroenterology & Hepatology

Targeted Delivery of Stk25 Antisense Oligonucleotides to Hepatocytes Protects Mice Against Nonalcoholic Fatty Liver Disease

Emmelie Cansby et al.

CELLULAR AND MOLECULAR GASTROENTEROLOGY AND HEPATOLOGY (2019)

添加到收藏夹

Article Pharmacology & Pharmacy

Efficacy of evogliptin and cenicriviroc against nonalcoholic steatohepatitis in mice: a comparative study

Zheng Wang et al.

KOREAN JOURNAL OF PHYSIOLOGY & PHARMACOLOGY (2019)

添加到收藏夹

Article Gastroenterology & Hepatology

The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases

Naga Chalasani et al.

HEPATOLOGY (2018)

添加到收藏夹

Article Gastroenterology & Hepatology

Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease

Chris Estes et al.

HEPATOLOGY (2018)

添加到收藏夹

Article Gastroenterology & Hepatology

Randomised clinical trial: a leucine-metformin-sildenafil combination (NS-0200) vs placebo in patients with non-alcoholic fatty liver disease

N. Chalasani et al.

ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2018)

添加到收藏夹

Article Endocrinology & Metabolism

Dulaglutide decreases plasma aminotransferases in people with Type 2 diabetes in a pattern consistent with liver fat reduction: a post hoc analysis of the AWARD programme

K. Cusi et al.

DIABETIC MEDICINE (2018)

添加到收藏夹

Article Gastroenterology & Hepatology

Simtuzumab Is Ineffective for Patients With Bridging Fibrosis or Compensated Cirrhosis Caused by Nonalcoholic Steatohepatitis

Stephen A. Harrison et al.

GASTROENTEROLOGY (2018)

添加到收藏夹

Article Gastroenterology & Hepatology

Miglitol attenuates non-alcoholic steatohepatitis in diabetic patients

Michiharu Komatsu et al.

HEPATOLOGY RESEARCH (2018)

添加到收藏夹

Review Endocrinology & Metabolism

The effect of antidiabetic medications on non-alcoholic fatty liver disease (NAFLD)

Laura Iogna Prat et al.

HORMONES-INTERNATIONAL JOURNAL OF ENDOCRINOLOGY AND METABOLISM (2018)

添加到收藏夹

Article Gastroenterology & Hepatology

A Multi-strain Probiotic Reduces the Fatty Liver Index, Cytokines and Aminotransferase levels in NAFLD Patients: Evidence from a Randomized Clinical Trial

Nazarii Kobyliak et al.

JOURNAL OF GASTROINTESTINAL AND LIVER DISEASES (2018)

添加到收藏夹

Meeting Abstract Gastroenterology & Hepatology

Elafibranor and nitazoxanide synergize to reduce fibrosis in a NASH model

R. Walczak et al.

JOURNAL OF HEPATOLOGY (2018)

添加到收藏夹

Article Multidisciplinary Sciences

Gemcabene downregulates inflammatory, lipid-altering and cell-signaling genes in the STAM™ model of NASH

Daniela Carmen Oniciu et al.

PLOS ONE (2018)

添加到收藏夹

Article Gastroenterology & Hepatology

INT-767 improves histopathological features in a diet-induced ob/ob mouse model of biopsy-confirmed nonalcoholic steatohepatitis

Jonathan D. Roth et al.

WORLD JOURNAL OF GASTROENTEROLOGY (2018)

添加到收藏夹

Article Endocrinology & Metabolism

Hepatic regulation of VLDL receptor by PPAR beta/delta and FGF21 modulates non-alcoholic fatty liver disease

Mohammad Zarei et al.

MOLECULAR METABOLISM (2018)

添加到收藏夹

Article Nutrition & Dietetics

Omega-3 PUFA modulate lipogenesis, ER stress, and mitochondrial dysfunction markers in NASH - Proteomic and lipidomic insight

Livia Samara dos Reis Rodrigues Okada et al.

CLINICAL NUTRITION (2018)

添加到收藏夹

Editorial Material Biochemistry & Molecular Biology

Hepatic thyroid hormone receptor β1 agonism: good for lipids, good for bile?

Paul A. Dawson et al.

JOURNAL OF LIPID RESEARCH (2018)

添加到收藏夹

Review Medicine, General & Internal

Omega-3 polyunsaturated fatty acid supplementation and non-alcoholic fatty liver disease A meta-analysis of randomized controlled trials

Jian-Hui Yan et al.

MEDICINE (2018)

添加到收藏夹

Article Gastroenterology & Hepatology

Effect of sitagliptin on hepatic histological activity and fibrosis of nonalcoholic steatohepatitis patients: a 1-year randomized control trial

Shahinul Alam et al.

HEPATIC MEDICINE-EVIDENCE AND RESEARCH (2018)

添加到收藏夹

Article Endocrinology & Metabolism

Efficacy of canagliflozin against nonalcoholic fatty liver disease: a prospective cohort study

Toshio Itani et al.

OBESITY SCIENCE & PRACTICE (2018)

添加到收藏夹

Article Endocrinology & Metabolism

Luseogliflozin improves liver fat deposition compared to metformin in type 2 diabetes patients with non-alcoholic fatty liver disease: A prospective randomized controlled pilot study

Takashi Shibuya et al.

DIABETES OBESITY & METABOLISM (2018)

添加到收藏夹

Article Gastroenterology & Hepatology

Effect of sodium glucose cotransporter 2 inhibitor on liver function tests in Japanese patients with non-alcoholic fatty liver disease and type 2 diabetes mellitus

Yuya Seko et al.

HEPATOLOGY RESEARCH (2017)

添加到收藏夹

Article Immunology

Compact bone-derived mesenchymal stem cells attenuate nonalcoholic steatohepatitis in a mouse model by modulation of CD4 cells differentiation

Huafeng Wang et al.

INTERNATIONAL IMMUNOPHARMACOLOGY (2017)

添加到收藏夹

Article Medicine, General & Internal

Lobeglitazone, a Novel Thiazolidinedione, Improves Non-Alcoholic Fatty Liver Disease in Type 2 Diabetes: Its Efficacy and Predictive Factors Related to Responsiveness

Yong-ho Lee et al.

JOURNAL OF KOREAN MEDICAL SCIENCE (2017)

添加到收藏夹

Article Gastroenterology & Hepatology

Effects of Probiotics on Nonalcoholic Fatty Liver Disease in Obese Children and Adolescents

Fatemeh Famouri et al.

JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION (2017)

添加到收藏夹

Review Gastroenterology & Hepatology

Antioxidant dietary approach in treatment of fatty liver: New insights and updates

Alessandra Ferramosca et al.

WORLD JOURNAL OF GASTROENTEROLOGY (2017)

添加到收藏夹

Article

Improvement of non-alcoholic steatohepatitis by hepatocyte-like cells generated from iPSCs with Oct4/Sox2/Klf4/Parp1

Yueh Chien et al.

Oncotarget (2017)

添加到收藏夹

Article Multidisciplinary Sciences

BAR502, a dual FXR and GPBAR1 agonist, promotes browning of white adipose tissue and reverses liver steatosis and fibrosis

Adriana Carino et al.

SCIENTIFIC REPORTS (2017)

添加到收藏夹

Article Medicine, Research & Experimental

Effects of Dapagliflozin on Body Composition and Liver Tests in Patients with Nonalcoholic Steatohepatitis Associated with Type 2 Diabetes Mellitus: A Prospective, Open-label, Uncontrolled Study

Hiroshi Tobita et al.

CURRENT THERAPEUTIC RESEARCH-CLINICAL AND EXPERIMENTAL (2017)

添加到收藏夹

Article Pharmacology & Pharmacy

Gemigliptin ameliorates Western-diet-induced metabolic syndrome in mice

Seung Hee Choi et al.

CANADIAN JOURNAL OF PHYSIOLOGY AND PHARMACOLOGY (2017)

添加到收藏夹

Article Pharmacology & Pharmacy

Selective Inhibition of Autotaxin Is Efficacious in Mouse Models of Liver Fibrosis

Gretchen Bain et al.

JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2017)

添加到收藏夹

Article Nutrition & Dietetics

Omega-3 polyunsaturated fatty acids in treating non-alcoholic steatohepatitis: A randomized, double-blind, placebo-controlled trial

Monize Aydar Nogueira et al.

CLINICAL NUTRITION (2016)

添加到收藏夹

Article Endocrinology & Metabolism

Exenatide decreases liver fat content and epicardial adipose tissue in patients with obesity and type 2 diabetes: a prospective randomized clinical trial using magnetic resonance imaging and spectroscopy

A. Dutour et al.

DIABETES OBESITY & METABOLISM (2016)

添加到收藏夹

Article Integrative & Complementary Medicine

The Therapeutic Effect of Berberine in the Treatment of Nonalcoholic Fatty Liver Disease: A Meta-Analysis

Xiaoyun Wei et al.

EVIDENCE-BASED COMPLEMENTARY AND ALTERNATIVE MEDICINE (2016)

添加到收藏夹

Article Gastroenterology & Hepatology

Efficacy of probiotics in non-alcoholic fatty liver disease in adult and children: A meta-analysis of randomized controlled trials

Xiaolin Gao et al.

HEPATOLOGY RESEARCH (2016)

添加到收藏夹

Article Gastroenterology & Hepatology

EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease

Giulio Marchesini et al.

JOURNAL OF HEPATOLOGY (2016)

添加到收藏夹

Article Medicine, General & Internal

Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study

Matthew James Armstrong et al.

LANCET (2016)

添加到收藏夹

Review Gastroenterology & Hepatology

Sirtuins and nonalcoholic fatty liver disease

Fatiha Nassir et al.

WORLD JOURNAL OF GASTROENTEROLOGY (2016)

添加到收藏夹

Article Multidisciplinary Sciences

Effectiveness of Omega-3 Polyunsaturated Fatty Acids in Non-Alcoholic Fatty Liver Disease: A Meta-Analysis of Randomized Controlled Trials

Xi-Xi He et al.

PLOS ONE (2016)

添加到收藏夹

Article Medicine, Research & Experimental

Efficacy of alogliptin in preventing non-alcoholic fatty liver disease progression in patients with type 2 diabetes

Tsuyoshi Mashitani et al.

BIOMEDICAL REPORTS (2016)

添加到收藏夹

Article Biochemistry & Molecular Biology

Heat Killed Lactobacillus reuteri GMNL-263 Reduces Fibrosis Effects on the Liver and Heart in High Fat Diet-Hamsters via TGF-β Suppression

Wei-Jen Ting et al.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2015)

添加到收藏夹

Article Endocrinology & Metabolism

An Insulin-Sensitizing Thiazolidinedione, Which Minimally Activates PPARγ, Does Not Cause Bone Loss

Tomohiro Fukunaga et al.

JOURNAL OF BONE AND MINERAL RESEARCH (2015)

添加到收藏夹

Article Medicine, General & Internal

Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial

Brent A. Neuschwander-Tetri et al.

LANCET (2015)

添加到收藏夹

Article Multidisciplinary Sciences

Eicosapentaenoic Acid Ameliorates Non-Alcoholic Steatohepatitis in a Novel Mouse Model Using Melanocortin 4 Receptor-Deficient Mice

Kuniha Konuma et al.

PLOS ONE (2015)

添加到收藏夹

Article Gastroenterology & Hepatology

Randomised clinical trial: the beneficial effects of VSL# 3 in obese children with non-alcoholic steatohepatitis

A. Alisi et al.

ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2014)

添加到收藏夹

Article Biotechnology & Applied Microbiology

Preventing non-alcoholic fatty liver disease through Lactobacillus johnsonii BS15 by attenuating inflammation and mitochondrial injury and improving gut environment in obese mice

Jinge Xin et al.

APPLIED MICROBIOLOGY AND BIOTECHNOLOGY (2014)

添加到收藏夹

Article Endocrinology & Metabolism

Osteocalcin Protects Against Nonalcoholic Steatohepatitis in a Mouse Model of Metabolic Syndrome

Anisha A. Gupte et al.

ENDOCRINOLOGY (2014)

添加到收藏夹

Article Medicine, General & Internal

Effect of Tesamorelin on Visceral Fat and Liver Fat in HIV-Infected Patients With Abdominal Fat Accumulation A Randomized Clinical Trial

Takara L. Stanley et al.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2014)

添加到收藏夹

Article Agriculture, Dairy & Animal Science

Effects of probiotic yogurt consumption on metabolic factors in individuals with nonalcoholic fatty liver disease

S. Nabavi et al.

JOURNAL OF DAIRY SCIENCE (2014)

添加到收藏夹

Review Endocrinology & Metabolism

Thyroid hormone receptors and resistance to thyroid hormone disorders

Tania M. Ortiga-Carvalho et al.

NATURE REVIEWS ENDOCRINOLOGY (2014)

添加到收藏夹

Article Biology

Linagliptin alleviates hepatic steatosis and inflammation in a mouse model of non-alcoholic steatohepatitis

Thomas Klein et al.

MEDICAL MOLECULAR MORPHOLOGY (2014)

添加到收藏夹

Review Biochemistry & Molecular Biology

Sirtuins in stress response: guardians of the genome

L. Bosch-Presegue et al.

ONCOGENE (2014)

添加到收藏夹

Review Gastroenterology & Hepatology

Effects of glucagon-like peptide-1 receptor agonists on non-alcoholic fatty liver disease and inflammation

Xing-Chun Wang et al.

WORLD JOURNAL OF GASTROENTEROLOGY (2014)

添加到收藏夹

Article Biochemistry & Molecular Biology

Lactobacillus plantarum NCU116 improves liver function, oxidative stress and lipid metabolism in rats with high fat diet induced non-alcoholic fatty liver disease

Chuan Li et al.

FOOD & FUNCTION (2014)

添加到收藏夹

Review Endocrinology & Metabolism

Action and therapeutic potential of oxyntomodulin

Alessandro Pocai

MOLECULAR METABOLISM (2014)

添加到收藏夹

Review Gastroenterology & Hepatology

Review article: a comparison of glucagon-like peptides 1 and 2

P. Janssen et al.

ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2013)

添加到收藏夹

Review Oncology

Metabolic regulation of sirtuins upon fasting and the implication for cancer

Yueming Zhu et al.

CURRENT OPINION IN ONCOLOGY (2013)

添加到收藏夹

Article Gastroenterology & Hepatology

Efficacy and Safety of the Farnesoid X Receptor Agonist Obeticholic Acid in Patients With Type 2 Diabetes and Nonalcoholic Fatty Liver Disease

Sunder Mudaliar et al.

GASTROENTEROLOGY (2013)

添加到收藏夹

Article Medicine, Research & Experimental

The TGR5 receptor mediates bile acid-induced itch and analgesia

Farzad Alemi et al.

JOURNAL OF CLINICAL INVESTIGATION (2013)

添加到收藏夹

Article Multidisciplinary Sciences

Regression of Fibrosis and Reversal of Cirrhosis in Rats by Galectin Inhibitors in Thioacetamide-Induced Liver Disease

Peter G. Traber et al.

PLOS ONE (2013)

添加到收藏夹

Article Chemistry, Multidisciplinary

Synthetic FXR Agonist GW4064 Prevents Diet-Induced Hepatic Steatosis and Insulin Resistance

Yongjie Ma et al.

PHARMACEUTICAL RESEARCH (2013)

添加到收藏夹

Article Gastroenterology & Hepatology

Effects of probiotics on nonalcoholic fatty liver disease: A meta-analysis

Yan-Yan Ma et al.

WORLD JOURNAL OF GASTROENTEROLOGY (2013)

添加到收藏夹

Article Gastroenterology & Hepatology

Treatment of nonalcoholic steatohepatitis with probiotics. A proof-of-concept study

Vincent Wai-Sun Wong et al.

ANNALS OF HEPATOLOGY (2013)

添加到收藏夹

Article Gastroenterology & Hepatology

Bifidobacterium longum with Fructo-Oligosaccharides in Patients with Non Alcoholic Steatohepatitis

Michele Malaguarnera et al.

DIGESTIVE DISEASES AND SCIENCES (2012)

添加到收藏夹

Review Gastroenterology & Hepatology

Omega-3 supplementation and non-alcoholic fatty liver disease: A systematic review and meta-analysis

Helen M. Parker et al.

JOURNAL OF HEPATOLOGY (2012)

添加到收藏夹

Article Biochemistry & Molecular Biology

The use of stable isotope-labeled glycerol and oleic acid to differentiate the hepatic functions of DGAT1 and-2

Jenson Qi et al.

JOURNAL OF LIPID RESEARCH (2012)

添加到收藏夹

Article Oncology

Nifedipine prevents hepatic fibrosis in a non-alcoholic steatohepatitis model induced by an L-methionine-and choline-deficient diet

Hironori Nakagami et al.

MOLECULAR MEDICINE REPORTS (2012)

添加到收藏夹

Review Physiology

Toll-like receptors in liver fibrosis: cellular crosstalk and mechanisms

Ling Yang et al.

FRONTIERS IN PHYSIOLOGY (2012)

添加到收藏夹

Article Pediatrics

Docosahexaenoic acid supplementation decreases liver fat content in children with non-alcoholic fatty liver disease: double-blind randomised controlled clinical trial

Valerio Nobili et al.

ARCHIVES OF DISEASE IN CHILDHOOD (2011)

添加到收藏夹

Review Biochemistry & Molecular Biology

Role of thyroid receptor β in lipid metabolism

Camilla Pramfalk et al.

BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE (2011)

添加到收藏夹

Article Endocrinology & Metabolism

Exenatide decreases hepatic fibroblast growth factor 21 resistance in non-alcoholic fatty liver disease in a mouse model of obesity and in a randomised controlled trial

S. L. Samson et al.

DIABETOLOGIA (2011)

添加到收藏夹

Article Pharmacology & Pharmacy

Effects of bezafibrate in nonalcoholic steatohepatitis model mice with monosodium glutamate-induced metabolic syndrome

Yoshiyuki Sasaki et al.

EUROPEAN JOURNAL OF PHARMACOLOGY (2011)

添加到收藏夹

Article Gastroenterology & Hepatology

Intravenous administration of multipotent stromal cells prevents the onset of non-alcoholic steatohepatitis in obese mice with metabolic syndrome

Marcelo Ezquer et al.

JOURNAL OF HEPATOLOGY (2011)

添加到收藏夹

Article Gastroenterology & Hepatology

Effects of Lactobacillus rhamnosus Strain GG in Pediatric Obesity-related Liver Disease

Pietro Vajro et al.

JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION (2011)

添加到收藏夹

Article Medicine, Research & Experimental

SIRT1 as a potential therapeutic target for treatment of nonalcoholic fatty liver disease

Yasar Colak et al.

MEDICAL SCIENCE MONITOR (2011)

添加到收藏夹

Article Medicine, Research & Experimental

Fatty Acid Bile Acid Conjugate Inhibits Hepatic Stearoyl Coenzyme A Desaturase and Is Non-atherogenic

Alicia Leikin-Frenkel et al.

ARCHIVES OF MEDICAL RESEARCH (2010)

添加到收藏夹

Article Gastroenterology & Hepatology

A pilot trial of fenofibrate for the treatment of non-alcoholic fatty liver disease

C. Fernandez-Miranda et al.

DIGESTIVE AND LIVER DISEASE (2008)

添加到收藏夹

Article Gastroenterology & Hepatology

Randomized, placebo-controlled trial of pioglitazone in nondiabetic subjects with nonalcoholic steatohepatitis

Guruprasad P. Aithal et al.

GASTROENTEROLOGY (2008)

添加到收藏夹

Article Multidisciplinary Sciences

Small molecule activators of SIRT1 as therapeutics for the treatment of type 2 diabetes

Jill C. Milne et al.

NATURE (2007)

添加到收藏夹

Article Gastroenterology & Hepatology

Inhibiting triglyceride synthesis improves hepatic steatosis but exacerbates liver damage and fibrosis in obese mice with nonalcoholic steatohepatitis

Kanji Yamaguchi et al.

HEPATOLOGY (2007)

添加到收藏夹

Article Nutrition & Dietetics

n-3 polyunsaturated fatty acids, inflammation, and inflammatory diseases

Philip C. Calder

AMERICAN JOURNAL OF CLINICAL NUTRITION (2006)

添加到收藏夹

Article Medicine, General & Internal

Effect of multifactorial treatment on non-alcoholic fatty liver disease in metabolic syndrome: a randomised study

Vasilios G. Athyros et al.

CURRENT MEDICAL RESEARCH AND OPINION (2006)

添加到收藏夹

Article Medicine, Research & Experimental

Polyunsaturated fatty acids suppress glycolytic and lipogenic genes through the inhibition of ChREBP nuclear protein translocation

R Dentin et al.

JOURNAL OF CLINICAL INVESTIGATION (2005)

添加到收藏夹

Pharmacotherapy for Non-Alcoholic Fatty Liver Disease: Emerging Targets and Drug Candidates

相关参考文献